Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CID-103
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CASI Doses First Patient in Phase 1/2 CID-103 Trial for Thrombocytopenia
Details : CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody, which is currently being evaluated for the treatment of chronic immune thrombocytopenia in adults.
Product Name : CID-103
Product Type : Antibody
Upfront Cash : Inapplicable
January 06, 2025
Lead Product(s) : CID-103
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CID-103
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CASI Gets CTA Approval in China for CID-103 in Immune Thrombocytopenia
Details : CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody, which is currently being evaluated for the treatment of chronic immune thrombocytopenia in adults.
Product Name : CID-103
Product Type : Antibody
Upfront Cash : Inapplicable
October 24, 2024
Lead Product(s) : CID-103
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CID-103
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Gebro Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
CASI Pharmaceuticals Plans IND Submission for CID-103 and Receives Acquisition Proposal
Details : CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody, being investigated for the treatment of antibody-mediated rejection ("AMR") in kidney transplant.
Product Name : CID-103
Product Type : Antibody
Upfront Cash : Inapplicable
June 26, 2024
Lead Product(s) : CID-103
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Gebro Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CID-103
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CASI Pharmaceuticals Receives FDA IND Clearance for CID-103 in Immune Thrombocytopenia
Details : CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody, which is currently being evaluated for the treatment of chronic immune thrombocytopenia in adults.
Product Name : CID-103
Product Type : Antibody
Upfront Cash : Inapplicable
May 15, 2024
Lead Product(s) : CID-103
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB-5339 Tosylate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Cleave Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CB-5339 is an oral second-generation, small molecule VCP/p97 inhibitor, and is currently in Phase 1 clinical trial in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms.
Product Name : CB-5339
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2023
Lead Product(s) : CB-5339 Tosylate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Cleave Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inaticabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CNCT19 (Inaticabtagene Autoleucel), is the first CAR-T cell therapy for the treatment of B-ALL submitted for NDA and has the potential to be the first approved domestic developed CD19 directed CAR-T therapy in China.
Product Name : CNCT19
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Inaticabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI-1206,Rituximab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : BioInvent
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI-1206, a first-in-class fully human monoclonal antibody (mAb) that targets FcγRIIB, in combination with rituximab in patients with relapsed/refractory Non-Hodgkin's Lymphoma (NHL).
Product Name : BI-1206
Product Type : Antibody
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : BI-1206,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : BioInvent
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Under the terms of the agreement, CASI shall maintain the exclusive commercialization and co-marketing rights of CID-103 in autoimmune indications and book all revenue in the United States.
Product Name : CID-103
Product Type : Antibody
Upfront Cash : $10.0 million
May 24, 2022
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Xi'an Guokang Ruijin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Casi Pharmaceuticals Announces Renewal Of Exclusive Distribution Agreement For Evomela® In China
Details : Under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., will continue to be the sole distributor for the sale of EVOMELA® (melphalan) for Injection in China.
Product Name : Evomela
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
April 03, 2022
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Xi'an Guokang Ruijin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : CID-103
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CASI Pharmaceuticals has submitted a Clinical Trial Application with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for CID-103, its novel anti-CD38 monoclonal antibody for the treatment of multiple myeloma and other hematolog...
Product Name : CID-103
Product Type : Antibody
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : CID-103
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable